CD274 and plasma cell myeloma: Additionally, previous studies have reported that the efficacy of PD‐L1 blockade in myeloma patients is limited.[33] One possible reason is that some myeloma patients have low expression levels of PD‐L1 on their tumor cells, rendering them insensitive to PD‐L1 antibody therapy.